Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

Herman M, Okoji O, Castaneda D, Jirru E, Kotler D

MeSH — NLM indexing Aspartate Aminotransferases Hepacivirus Hepatitis C Humans Liver Cirrhosis Platelet Count

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Letter Independent Group United States

Authors (5)

Herman M — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Okoji O — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Castaneda D — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Jirru E — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Kotler D — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.

Citation

Herman M, Okoji O, Castaneda D, Jirru E, Kotler D. Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients. Aliment Pharmacol Ther. 2017;45(1):190-191. doi:10.1111/apt.13836.

Identifiers

DOI: 10.1111/apt.13836
PMID: 27910146

Tests

Liver diseases

Liver injuries

Comparisons

Subjects

Region

Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.